The phase III clinical study, to be conducted in 15 sites across India, will evaluate the immunogenicity and safety of Biological E's vaccine candidate in 1,268 healthy subjects
from Companies https://ift.tt/3xkWd5h
via IFTTT
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
Solar cells made of perovskite hold much promise for the future of solar energy. However, the material degrades quickly, severely limiting i...
-
With 73,642 new daily recoveries, the most so far, India's recovery rate has improved to 77.32%, while death rate has come down to 1.72%...
-
Although organ failure can be fatal, your kidneys, heart, and liver are prepared for this catastrophe. Emerging research supports the findin...
No comments:
Post a Comment